News
Public · Published
Truist Securities maintains HCA Healthcare at Buy, raises price target to $510 from $495
Truist Securities maintained a Buy rating on HCA Healthcare and raised its price target to $510 from $495, a 3.0% increase. The new target implies 9.0% upside from the November 2 close of $467.73.
Published:
Updated:
What happened
Truist Securities maintained a Buy rating on HCA Healthcare and raised its price target to $510 from $495, a 3.0% increase. The new target implies 9.0% upside from the November 2 close of $467.73.
Confirmed
Global impact / market context
A higher price target signals that Truist expects more share price upside, which can draw investor attention to HCA. The 9.0% implied gain suggests the analyst sees room for the stock to rise from its recent close.
Analyst inference
Recent analyst targets on HCA range from $401 to $521, with ratings spanning Equal-Weight to Buy and Overweight. Truist's $510 target sits near the high end but below the $521 target, suggesting mostly positive analyst views with some caution.
Analyst inference
What to watch
- Watch whether HCA trades toward Truist's $510 target or stays near the $467.73 November 2 close, a gap Truist frames as 9.0% upside. Confirmed
- Watch for new analyst notes on HCA and whether other firms raise targets, since the current range of $401 to $521 shows differing views on upside. Proposed
- Watch HCA's next financial results and guidance for signs that support the higher target, since analyst targets often depend on expected profit and revenue trends. Analyst inference
Evidence
- Original source link unavailable